|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1993-8-26
|
|
pubmed:abstractText |
In an attempt to assess the response to treatment and survival of a group of patients treated with standard chemotherapy and radiotherapy, we undertook a retrospective review of small-cell lung cancer (SCLC) patients treated by the University of Toronto Lung Oncology Group.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1592-7
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8393098-Adult,
pubmed-meshheading:8393098-Aged,
pubmed-meshheading:8393098-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8393098-Carcinoma, Small Cell,
pubmed-meshheading:8393098-Combined Modality Therapy,
pubmed-meshheading:8393098-Female,
pubmed-meshheading:8393098-Humans,
pubmed-meshheading:8393098-Lung Neoplasms,
pubmed-meshheading:8393098-Male,
pubmed-meshheading:8393098-Middle Aged,
pubmed-meshheading:8393098-Neoplasm Staging,
pubmed-meshheading:8393098-Prognosis,
pubmed-meshheading:8393098-Survival Analysis
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Importance of clinical staging in limited small-cell lung cancer: a valuable system to separate prognostic subgroups. The University of Toronto Lung Oncology Group.
|
|
pubmed:affiliation |
Department of Medicine, Toronto Hospital, Ontario, Canada.
|
|
pubmed:publicationType |
Journal Article
|
